Key statistics dashboard for Artiva Biotherapeutics, Inc. (ARTV). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy.
Stock Data
| Price | $8.60 |
| Market Cap | $420M |
| Enterprise Value | $128.9M |
| Beta | 1.48 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -2.60 |
| Price / Book | 0.98 |
| P/S | 0.00 |
| EV/EBITDA | -1.47 |
| EV/Sales | 0.00 |
| EV/FCF | -1.31 |
| P/FCF | -4.29 |
| Earnings Yield | -26.79% |
| FCF Yield | -23.33% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -53.86% |
| Return on Assets | -24.64% |
| Return on Invested Capital | -26.91% |
| Return on Capital Employed | -27.16% |
Financial Health
| Current Ratio | 24.16 |
| Quick Ratio | 24.16 |
| Cash Ratio | 20.67 |
| Debt / Equity | 0.03 |
| Debt / Assets | 2.67% |
| Net Debt / EBITDA | 3.33 |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 8.82 |
| Cash per share | 8.86 |
| FCF per share | -2.49 |
| Tangible Book Value per share | 8.82 |
| Dividend per share | 0.00 |
Related companies: ADVM · ALXO · CNTB · DTIL · GUTS · IFRX · MGX
Explore sector: Healthcare · Biotechnology
More sections of ARTV: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks